Analyst consensus rating
Aptevo Therapeutics Analyst Rating: Strong Buy
APVO is rated Strong Buy by 2 analysts with a $25.50 target. As of 2026-08-30.
Direct answer
Aptevo Therapeutics's consensus rating is Strong Buy.
2 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $25.50.
Forecast evidence checked August 30, 2026.
Get free Aptevo Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $2.37
- Average price target
- $25.50
- High price target
- $30.00
- Low price target
- $21.00
- Low target gap
- +787.9%
- Target upside
- +978.2%
- High target gap
- +1,168.5%
- Target range width
- 380.5%
- Consensus rating
- Strong Buy
- Analysts
- 2
- Evidence date
- August 30, 2026
- Valid through
- September 6, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Aptevo Therapeutics?
Aptevo Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $25.50.
How far are Aptevo Therapeutics's low and high targets from the recorded price?
The low target implies +787.9%, while the high target implies +1,168.5%.
How many analysts are included in Aptevo Therapeutics's consensus?
The verified consensus includes 2 analysts.
How is Aptevo Therapeutics's target upside or downside calculated?
The average target of $25.50 is divided by the recorded price of $2.37, then one is subtracted to produce +978.2%. This does not guarantee a future return.
When was Aptevo Therapeutics's analyst forecast verified?
The data was verified on 2026-08-30. The dataset is valid through 2026-09-06.